Study Title: MK0646 for Patients with Advanced Cancer
Category: Cancer, General
Currently accepting participants?
Not at this time.
Principal Investigator: Vincent Picozzi
Study Coordinator: Andrea Jacks
Phone: 206-625-7373 Ext.63979
Email: andrea.jacks@vmmc.org
What is the MK0646 for Patients with Advanced Cancer study?
This is a multicenter, open-label, non-randomized Phase Ib trial of MK-0646 conducted in three parts as an every other week one to two hour intravenous (IV) infusion.
Who can participate?
*Study not recruiting* (Direct patients to MK-2461 as that study has similar inclusion/exclusion criteria and is recruiting)
Patient must have a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard
therapy, or for which standard therapy does not exist. There is no limit on the number of prior treatment regimens.
Study Summary:
Phase Ib trial of MK-0646 treatment for relapsed or refractory locally advanced or metastatic cancers.
Detailed Study Description:
(No information)
Study Design: Interventional
Phase of Study: Phase I
Study Type: Interventional
Condition or Study Focus: Advanced Cancer
Intervention Type: Biological Therapy
Intervention Name: MK-0646
Gender: Male and Female
Age group: Interventional
Sponsor: Merck
Other studies in this category include:
Studies currently accepting study participants:
Studies currently not accepting study participants:
- A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
- AMC045: HIV-Associated Anal Cancer
- Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study
- Investigational drug vs. Placebo for Patients with Renal Cell Carcinoma (Kidney Cancer) at High Risk of Recurrence after Surgery
- Kidney Cancer (Renal Cell Carcinoma): Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)
- Liver Cancer (Hepatocellular Carcinoma): Sorafenib vs Placebo as Adjuvant Treatment
- Liver Cancer (Hepatocellular Carcinoma): Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable (Advanced or Metastatic) Liver Cancer
- Liver Cancer (Hepatocellular Carcinoma): TACE for Intermediate Stage
- MK0646 for Patients with Advanced Cancer
- Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218)
- Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Sorafenib v. Sunitinib v. Placebo for High Risk Renal Cell Carcinoma Patients
- Trial of FOLFOX with or without cetuximab for colon cancer
- Use of Human Corticotropin-Releasing Factor (hCRF) to Control Brain Swelling (edema) in Brain Tumor Patients
- Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer